Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.

Bilder RM, Loo SK, McGough JJ, Whelan F, Hellemann G, Sugar C, Del'Homme M, Sturm A, Cowen J, Hanada G, McCracken JT.

J Am Acad Child Adolesc Psychiatry. 2016 Aug;55(8):667-73. doi: 10.1016/j.jaac.2016.05.016. Epub 2016 Jun 7.

PMID:
27453080
2.

Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.

McCracken JT, McGough JJ, Loo SK, Levitt J, Del'Homme M, Cowen J, Sturm A, Whelan F, Hellemann G, Sugar C, Bilder RM.

J Am Acad Child Adolesc Psychiatry. 2016 Aug;55(8):657-666.e1. doi: 10.1016/j.jaac.2016.05.015. Epub 2016 Jun 3.

3.

The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain.

Mather M, Harley CW.

Trends Cogn Sci. 2016 Mar;20(3):214-26. doi: 10.1016/j.tics.2016.01.001. Review.

4.

Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.

Huss M, Chen W, Ludolph AG.

Clin Drug Investig. 2016 Jan;36(1):1-25. doi: 10.1007/s40261-015-0336-0. Review.

5.

Facilitation of spatial working memory performance following intra-prefrontal cortical administration of the adrenergic alpha1 agonist phenylephrine.

Hvoslef-Eide M, Oomen CA, Fisher BM, Heath CJ, Robbins TW, Saksida LM, Bussey TJ.

Psychopharmacology (Berl). 2015 Nov;232(21-22):4005-16. doi: 10.1007/s00213-015-4038-3. Epub 2015 Aug 12.

6.

Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents.

Bello NT.

Patient Prefer Adherence. 2015 Jun 30;9:877-85. doi: 10.2147/PPA.S73167. eCollection 2015. Review.

7.

Neurocognitive dysfunction and pharmacological intervention using guanfacine in a rhesus macaque model of self-injurious behavior.

Freeman ZT, Rice KA, Soto PL, Pate KA, Weed MR, Ator NA, DeLeon IG, Wong DF, Zhou Y, Mankowski JL, Zink MC, Adams RJ, Hutchinson EK.

Transl Psychiatry. 2015 May 19;5:e567. doi: 10.1038/tp.2015.61.

8.

Hepatocyte nuclear factor 4 alpha is a key factor related to depression and physiological homeostasis in the mouse brain.

Yamanishi K, Doe N, Sumida M, Watanabe Y, Yoshida M, Yamamoto H, Xu Y, Li W, Yamanishi H, Okamura H, Matsunaga H.

PLoS One. 2015 Mar 16;10(3):e0119021. doi: 10.1371/journal.pone.0119021. eCollection 2015.

9.

Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings.

Fredriksson I, Jayaram-Lindström N, Wirf M, Nylander E, Nyström E, Jardemark K, Steensland P.

Neuropsychopharmacology. 2015 Mar 13;40(5):1130-40. doi: 10.1038/npp.2014.294.

10.

The role of prefrontal catecholamines in attention and working memory.

Clark KL, Noudoost B.

Front Neural Circuits. 2014 Apr 8;8:33. doi: 10.3389/fncir.2014.00033. eCollection 2014. Review. Erratum in: Front Neural Circuits. 2014;8:142.

11.

The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.

Fox H, Sinha R.

Adv Pharmacol. 2014;69:217-65. doi: 10.1016/B978-0-12-420118-7.00006-8. Review.

12.

Norepinephrine and impulsivity: effects of acute yohimbine.

Swann AC, Lijffijt M, Lane SD, Cox B, Steinberg JL, Moeller FG.

Psychopharmacology (Berl). 2013 Sep;229(1):83-94. doi: 10.1007/s00213-013-3088-7. Epub 2013 Apr 6.

13.

Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control.

Schulz KP, Clerkin SM, Fan J, Halperin JM, Newcorn JH.

Psychopharmacology (Berl). 2013 Mar;226(2):261-71. doi: 10.1007/s00213-012-2893-8. Epub 2012 Oct 20.

14.

Dopamine beta hydroxylase genotype identifies individuals less susceptible to bias in computer-assisted decision making.

Parasuraman R, de Visser E, Lin MK, Greenwood PM.

PLoS One. 2012;7(6):e39675. doi: 10.1371/journal.pone.0039675. Epub 2012 Jun 27.

15.

Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings.

Fox HC, Seo D, Tuit K, Hansen J, Kimmerling A, Morgan PT, Sinha R.

J Psychopharmacol. 2012 Jul;26(7):958-72. doi: 10.1177/0269881111430746. Epub 2012 Jan 9.

16.

An in vitro evaluation of guanfacine as a substrate for P-glycoprotein.

Gillis NK, Zhu HJ, Markowitz JS.

Neuropsychiatr Dis Treat. 2011;7:501-5. doi: 10.2147/NDT.S24153. Epub 2011 Aug 26.

17.

Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response.

McAllister TW, McDonald BC, Flashman LA, Ferrell RB, Tosteson TD, Yanofsky NN, Grove MR, Saykin AJ.

Int J Psychophysiol. 2011 Oct;82(1):107-14. doi: 10.1016/j.ijpsycho.2011.06.022. Epub 2011 Jul 19.

18.

Cognitive enhancers for the treatment of ADHD.

Bidwell LC, McClernon FJ, Kollins SH.

Pharmacol Biochem Behav. 2011 Aug;99(2):262-74. doi: 10.1016/j.pbb.2011.05.002. Epub 2011 May 10. Review.

19.

Individual differences in cognition, affect, and performance: behavioral, neuroimaging, and molecular genetic approaches.

Parasuraman R, Jiang Y.

Neuroimage. 2012 Jan 2;59(1):70-82. doi: 10.1016/j.neuroimage.2011.04.040. Epub 2011 May 3. Review.

20.

Molecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders.

Gamo NJ, Arnsten AF.

Behav Neurosci. 2011 Jun;125(3):282-96. doi: 10.1037/a0023165. Review.

Supplemental Content

Support Center